VERZELE PHARMA
ActiveVERZELE PHARMA has been active since 2008 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €166k and a net result of €38k. Equity is growing by ~8.8% per year across the filed fiscal years. Its solvency ranks better than 46% of 10331 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
Checked score
Score 2025
75
/ 100
Excellent
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability78▲+4
Solvency58▲+5
Growth78▲+26
Track record100
Bankruptcy probability, 12 months
0.6%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €12k at 30 days acceptable
Liquidity ample (current ratio 2.33 against 2.4 in 2024; short-term debt: 33.8% and cash: 33.8% of total assets), but 66.8% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
33.2%
Return on assets
7.7%
Age of the figures
9 mo
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-08-2026, 28 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
28 d late
2024
28 d late
2023
19 d early
2022
26 d early
2021
24 d late
2020
26 d late
2019
45 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
20-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€166k▲ 6.7%
2024 · €156k
2018: €42k
2019: €92k
2020: €140k
2021: €118k
2022: €147k
2023: €156k
2024: €156k
2018 → 2025
Total assets
€501k▼ 9.1%
2024 · €551k
2018: €816k
2019: €751k
2020: €699k
2021: €725k
2022: €636k
2023: €641k
2024: €551k
2018 → 2025
Net result
€38k▲ 57.7%
2024 · €24k
2018: €33k
2019: €50k
2020: €48k
2021: €18k
2022: €65k
2023: €38k
2024: €24k
2018 → 2025
Working capital
€225k▼ 8.7%
2024 · €247k
2018: €130k
2019: €150k
2020: €205k
2021: €192k
2022: €225k
2023: €242k
2024: €247k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€118k-€147k▲ 24.4%€156k▲ 5.7%€156k▲ 0.2%€166k▲ 6.7%
Operating result€10k-€63k▲ 554%€46k▼ 27.3%€29k▼ 37.6%€43k▲ 50.8%
Net result€18k-€65k▲ 266%€38k▼ 40.8%€24k▼ 36.6%€38k▲ 57.7%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 51% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €501k
Fixed assets
€106k▼ 17.5%
Current assets
€394k▼ 6.6%
Equity and liabilities €501k
Equity
€166k▲ 6.7%
Debt
€334k▼ 15.4%
The debt ratio falls from 71.7% to 66.8%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€65k▼
2024 · €89k
Cash flow
€60k▼
2024 · €84k
Solvency
33.2%▲
2024 · 28.3%
Current ratio
2.33▼
2024 · 2.40
Quick ratio
1.59▲
2024 · 1.58
Debt / equity
2.01▼
2024 · 2.53
ROE
23.1%▲
2024 · 15.6%
ROA
7.7%▲
2024 · 4.4%
Interest coverage
10.64▼
2024 · 14.56
Debt
€334k▼
2024 · €395k
Debt ≤ 1 year
€169k▼
2024 · €176k
Debt > 1 year
€157k▼
2024 · €211k
Income taxes
€9k▼
2024 · €9k
Staff costs
€114k▲
2024 · €107k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€551k€501k▼
Fixed assets21/28€129k€106k▼
Tangible fixed assets22/27€124k€101k▼
Land and buildings22€118k€98k▼
Furniture and vehicles24€6k€3k▼
Financial fixed assets28€5k€5k=
Current assets29/58€422k€394k▼
Stocks and contracts in progress3€145k€125k▼
Stocks30/36€145k€125k▼
Amounts receivable within one year40/41€103k€87k▼
Trade receivables40€100k€84k▼
Other amounts receivable41€3k€3k▲
Cash at bank and in hand54/58€164k€169k▲
Deferred charges and accrued income490/1€11k€13k▲
Equity and liabilities
Total equity and liabilities10/49€551k€501k▼
Equity10/15€156k€166k▲
Contributions10/11€19k€19k=
Reserves13€137k€148k▲
Tax-exempt reserves132€1k€1k=
Distributable reserves133€136k€147k▲
Amounts payable17/49€395k€334k▼
Amounts payable after more than one year17€211k€157k▼
Financial debts170/4€211k€157k▼
Amounts payable within one year42/48€176k€169k▼
Current portion of amounts payable after more than one year42€54k€54k▲
Trade debts44€61k€53k▼
Suppliers440/4€61k€53k▼
Taxes, remuneration and social security45€37k€34k▼
Taxes450/3€17k€12k▼
Remuneration and social security454/9€20k€22k▲
Other amounts payable47/48€24k€28k▲
Accrued charges and deferred income492/3€8k€8k▲
Income statement
Code20242025
Non-recurring operating income76A-€3k
Remuneration, social security and pensions62€107k€114k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€60k€22k▼
Other operating charges640/8€8k€7k▼
Gross operating margin9900€203k€186k▼
Operating profit (loss)9901€29k€43k▲
Financial income75/76B€11k€10k▼
Recurring financial income75€11k€10k▼
Financial charges65/66B€6k€6k▲
Recurring financial charges65€6k€6k▲
Profit (loss) for the period before taxes9903€34k€47k▲
Income taxes67/77€9k€9k▼
Profit (loss) for the period9904€24k€38k▲
Profit (loss) for the period to be appropriated9905€24k€38k▲
Appropriation of the result
Profit (loss) to be appropriated9906€24k€38k▲
Transfer to equity691/2€363€10k▲
To other reserves6921€363€10k▲
Profit to be distributed694/7€24k€28k▲
Return on contributions (dividend)694€24k€16k▼
Directors or managers695-€12k
Social balance
Average headcount (FTE)90871.32.0▲
The notes to these accounts (18 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
28-08
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 28 days late
2025
28-08
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema · 28 days late
2024
12-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
31-12
Financial
Equity above €150kEq €156k ▲5.7%
6 profitable years in a row build equity to €156k.
05-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
31-12
Financial
Highest result since 2018net €65k ▲266%
Operating result €63k, net result €65k, both a record.
24-08
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema · 24 days late
2021
31-12
Financial
Weakest financial yearnet €18k ▼62.7%
Net result drops to €18k, the lowest in the series; recovery starts the following year.
26-08
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 26 days late
2020
31-12
Financial
Equity above €100kEq €140k ▲51.6%
3 profitable years in a row build equity to €140k.
14-09
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema · 45 days late
2019
23-09
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema · 54 days late
2018
31-08
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema · 31 days late
2017
30-08
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema · 30 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
4 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Oudenaarde · 1 establishment unit since 2008
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Diependale 89700 OudenaardeGround area
1,099 m²
Building footprint
544 m²
Volume, LiDAR
3,710 m³
2 parcels, Flanders · tallest building 12.8 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
VERZELE PHARMA
since 20082.170.183.176
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 45507A0106/02W002 | Flanders | 867 m² | 1 · 342 m² | 12.8 m · 2 fl. |
| 45002A0219/00E000 | Flanders | 231 m² | 1 · 202 m² | 11.4 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
1 of these parcels carry protected heritage (source: regional heritage registers, Onroerend Erfgoed / patrimoine.brussels).
Similar companies · same sector, comparable size
PHARMACIE BASILIQUE
BE 0821.770.142
Koekelberg · Eq €166k
VABO PHARMA
BE 0420.027.816
Menen · Eq €166k
APOTHEEK VAN DE WALLE-BLANCQUAERT
BE 0864.315.431
Gent · Eq €167k
PHARMACIE BERNARD
BE 0474.329.208
Tournai · Eq €167k
PHARMACIE REMILI-BASTIN
BE 0872.727.608
Chapelle-lez-Herlaimont · Eq €166k
Of 5,222 companies in sector 47730 we hold annual accounts for 3,861. 3,575 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded28-03-2008
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 18 filingsAddress and cadastre registers
Data from official sources, last processed on 18-09-2026. Scores and ratios are computed by Checked and are not a credit decision.